Allergan and Kythera Biopharmaceuticals have amended and restated their merger agreement. Allergan’s pending acquisition of Kythera now will be an all-cash consideration.

The structure of their previously announced transaction was for $75 per share to be paid to Kythera stockholders in an 80% cash and 20% stock transaction. The other terms of the amended and restated agreement are substantially similar to those in the original agreement.

Allergan and Kythera anticipate that the all-cash transaction provided for under the amended and restated agreement can be completed more quickly than the cash and stock transaction provided for under the terms of the original agreement.